Some Experts Think TransMedics Group (TMDX) Has a Near-Monopoly on Keeping Donor Organs Alive
Detailed summary
We recently released our ranking of the 10 Stocks That Could Skyrocket in 2027, and TransMedics Group (NASDAQ:TMDX) ranked 9th. SpaceX’s public debut in June gave investors a new…
We recently released our ranking of the 10 Stocks That Could Skyrocket in 2027, and TransMedics Group (NASDAQ:TMDX) ranked 9th.
SpaceX's public debut in June gave investors a new yardstick for how fast a space-linked stock can move, in both directions. Since then, shares of newer space companies have swung hard around SpaceX's latest report.
Yahoo Finance reported on October 21 that SpaceX opened with its biggest jump since the debut, after third-quarter revenue and profit beat Wall Street estimates. The company's AI business now brings in nearly half of its sales.
Elon Musk said on the earnings call that SpaceX and Tesla have each formed special committees of independent directors to study a combination, and that he cannot take part in the decision as a conflicted party, Yahoo Finance reported. Gene Munster of Deepwater Asset Management puts the odds of a deal within two years at 95%.
Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)
